Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) --Cullinan Therapeutics, Inc.(Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences:

Webcasts of the fireside chats will be available under the Events and Presentations section of the Company’s investor relations website athttps://investors.cullinantherapeutics.com/events.

Cullinan Therapeutics, Inc.(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan athttps://cullinantherapeutics.com/, and follow Cullinan onLinkedInandX.